Serum biomarkers in patients with psoriasis and coronary artery disease and their impact on hospitalization: data form a prospective, 4-year, single-center, uncontrolled study

Aim. To study serum biomarker profile in patients with coronary artery disease (CAD) and psoriasis and the impact on the incidence of hospitalization for cardiovascular reasons and psoriasis.

Material and methods. The study included 90 patients divided into following 3 groups: with psoriasis (n=30), coronary artery disease (CAD) (n=30) and CAD+psoriasis (n=30) in whom serum biomarkers were determined at the beginning of the study (growth stimulation expressed gene 2, N-terminal pro-brain natriuretic peptide (NT-proBNP), interleukin-17 and tumor necrosis factor alpha) and hospitalization rates were monitored over 4 years.

Results. There was a significant difference in the concentrations of all biomarkers between the groups (p<0,05), with the maximum values being in the CAD+psoriasis group, except for NT-proBNP. In regression analysis, risk factors for cardiovascular hospitalizations were psoriasis (p=0,049) and increased NT-proBNP concentrations (p<0,001).

Conclusion. Comorbidity leads to an increase in the serum concentration of biomarkers, while the risk factors for cardiovascular hospitalization were psoriasis and serum NT-proBNP level.

1. Khismatullina ZR, Amineva AM, Zagidullin NSh, et al. Psoriasis, psoriatic arthritis, metabolic disorders and cardiovascular disease. What is common? Russian Journal of Clinical Dermatology and Venereology. 2020;(6):137-45. (In Russ.) doi:10.17116/klinderma202019021137.

2. Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: Implications for management. J Am Acad Dermatol. 2017;76:393-403. doi:10.1016/j.jaad.2016.07.065.

3. Koch M, Baurecht H, Ried JS, et al. Psoriasis and cardiometabolic traits: Modest association but distinct genetic architectures. J Investig Dermatol. 2015;135:1283-93. doi:10.1038/jid.2015.8.

4. Gareeva DF, Khamitova AF, Lakman IA, et al. Prognostic significance of a combination of novel biomarkers in the long-term stratification of adverse outcomes in patients with ST-segment elevation myocardial infarction. Russian Journal of Cardiology. 2020;25(12):3948. (In Russ.) doi:10.15829/1560-4071-2020-3948.

5. Yeung H, Takeshita J, Mehta NN, et al. Psoriasis severity and the prevalence of major medical comorbidity: A population-based study. JAMA Dermatol. 2013;149:1173-9. doi:10.1001/jamadermatol.2013.5015.

6. Dowlatshahi EA, Kavousi M, Nijsten T, et al. Psoriasis is not associated with atherosclerosis and incident cardiovascular events: the Rotterdam Study. J Invest Dermatol. 2013;133(10):2347-54. doi:10.1038/jid.2013.131.

7. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735-41. doi:10.1001/jama.296.14.1735.

8. Polachek A, Touma Z, Anderson M, et al. Risk of cardiovascular morbidity in patients with psoriatic arthritis: a meta-analysis of observational studies. Arthritis. Care Res. (Hoboken). 2017;69(1):67-74. doi:10.1002/acr.22926.

9. Bayes-Genis A, Docherty KF, Petrie MC, et al. Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP: A clinical consensus statement from the Heart Failure Association of the ESC. Eur J Heart Fail. 2023;25(11):1891-8. doi:10.1002/ejhf.3036.

10. Savarimuthu S, Goel P, Harky A.Soluble ST2: a valuable prognostic marker in heart failure. Heart Fail Rev. 2022;27(6):2155-64. doi:10.1007/s10741-022-10258-2.

11. Jensen P, Skov L. Psoriasis and obesity. Dermatology. 2016;232:633-9. doi:10.1159/000455840.

12. Liu L , Cui S, Liu M, et al. Psoriasis Increased the Risk of Adverse Cardiovascular Outcomes: A New Systematic Review and Meta-Analysis of Cohort Study. Front Cardiovasc Med. 2022;25(9):829709. doi:10.3389/fcvm.2022.829709.

13. Gao N, Kong M, Li X, et al. The Association Between Psoriasis and Risk of Cardiovascular Disease: A Mendelian Randomization Analysis. Front. Immunol. 2022;13. doi:10.3389/fimmu.2022.918224.

14. Pietrzak A, Bartosinska J, Blaszczyk R, et al. Increased serum level of N-terminal Pro-Btype natriuretic peptide as a possible biomarker of cardiovascular risk in psoriatic patients. J Eur Acad Dermatol Venereol. 2015;29(5):1010-4. doi:10.1111/jdv.12528.

15. Colaco K, Lee K, Akhtari S, et al. Association of Cardiac Biomarkers With Cardiovascular Outcomes in Patients With Psoriatic Arthritis and Psoriasis: A Longitudinal Cohort Study. Arthritis Rheumatol. 2022;74(7):1184-92. doi:10.1002/art.42079.

16. Pourani M , Abdollahimajd F, Zargari O, et al. Soluble biomarkers for diagnosis, monitoring, and therapeutic response assessment in psoriasis. J Dermatolog Treat. 2022;33(4):1967- 74. doi:10.1080/09546634.2021.1966357.